271 related articles for article (PubMed ID: 24837659)
1. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
[TBL] [Abstract][Full Text] [Related]
2. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Dutreix C; Lorenzo S; Wang Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):915-20. PubMed ID: 24839948
[TBL] [Abstract][Full Text] [Related]
4. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
5. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
6. An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.
Jiang X; Dutreix C; Jarugula V; Rebello S; Won CS; Sun H
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):19-26. PubMed ID: 27138546
[TBL] [Abstract][Full Text] [Related]
7. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
[TBL] [Abstract][Full Text] [Related]
8. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
9. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Penzak SR; Rojas-Fernandez C
J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
11. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Rodrigues AD; Wood LS; Vourvahis M; Rowland A
Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
[TBL] [Abstract][Full Text] [Related]
12. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
14. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
[TBL] [Abstract][Full Text] [Related]
16. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
17. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?
Yang Z; Rodrigues AD
J Clin Pharmacol; 2010 Nov; 50(11):1330-8. PubMed ID: 20197489
[TBL] [Abstract][Full Text] [Related]
18. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity.
Hukkanen J; Puurunen J; Hyötyläinen T; Savolainen MJ; Ruokonen A; Morin-Papunen L; Orešič M; Piltonen T; Tapanainen JS
Br J Clin Pharmacol; 2015 Sep; 80(3):473-9. PubMed ID: 26095142
[TBL] [Abstract][Full Text] [Related]
19. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction.
Mårde Arrhén Y; Nylén H; Lövgren-Sandblom A; Kanebratt KP; Wide K; Diczfalusy U
Br J Clin Pharmacol; 2013 Jun; 75(6):1536-40. PubMed ID: 23116409
[TBL] [Abstract][Full Text] [Related]
20. Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs.
Liu R; Ma B; Mok MM; Murray BP; Subramanian R; Lai Y
Drug Metab Dispos; 2024 Feb; 52(3):236-241. PubMed ID: 38123963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
